FDA approves Biogen’s aducanumab
Aducanumab is the first new dementia drug treatment to come to market since 2003.
News & events
News, conferences, events, blogs and updates from across the field of dementia and the work of Alzheimer's Disease International.
Featured news and events
From Plan to Impact report launch
The report launch of From Plan to Impact IV: Progress towards targets of the WHO Global action plan on dementia will take place virtually on 26 May.
Alzheimers New Zealand Conference
Living with dementia: Taking action for a better future
Address: New Zealand / Online
IX National Alzheimer’s Congress
CEAFA faces with renewed enthusiasm the organization of its IX National Alzheimer's Congress in the city of Vitoria-Gasteiz, together with the Euskadi Alzheimer's Federation and its member associations, established in the three historic territories of the Basque Autonomous Community.
Address: Europa Palacio de Congresos, Vitoria-Gasteiz, Spain
15th World Congress on Controversies in Neurology (CONy)
Back in-person for 2021, CONy provides a platform for international experts on neurology to discuss and compare experiences.
Address: Dubai, United Arab Emirates
Youth and dementia: the value in volunteerism and community work
Third year university students in Bandar Seri Begawan, Brunei Drussalam reflect on their community experience with ADI member demensia Brunei (dB).
European and Caribbean regional member meetings
ADI members in the European and Caribbean regions took part in the first regional meetings of 2021 and since the COVID-19 pandemic began in early 2020.
ADI submits World Health Assembly statement on COVID-19, dementia and future preparedness
As the 74th World Health Assembly begins, ADI is sharing a statement submitted to the World Health Organization (WHO) and Member States.
The Davos Alzheimer’s Collaborative: A global preparedness plan for dementia
Davos Alzheimer's Collaborative (DAC) Co-chairs, Arnaud Bernaert and George Vradenburg, write about how DAC is building a coalition in order to accelerate Alzheimer's and dementia innovation.